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ABSTRACT 
 
The cancer anorexia-cachexia syndrome (CACS) is a frequent and severe condition in 
cancer patients. Currently, no pharmacological treatment is approved for the therapy 
of CACS. Centrally, glucagon-like peptide-1 (GLP-1) is expressed in the nucleus 
tractus solitarii (NTS) and is implicated in malaise, nausea and food aversion. The 
NTS is reciprocally connected to brain sites implicated in the control of energy 
balance including the area postrema (AP), which mediates CACS in certain tumour 
models. Given the role of GLP-1 as a mediator of anorexia under acute sickness 
conditions, we hypothesized that brainstem GLP-1 signalling might play a role in the 
mediation of CACS. 
Using hepatoma tumour-bearing (TB) rats, we first tested whether the chronic 
delivery of the GLP-1R antagonist exendin-9 (Ex-9) into the fourth ventricle 
attenuates CACS. Second, we investigated whether a genetic knockdown of GLP-1 
expression in the NTS ameliorates CACS.  
 
Ex-9 attenuated anorexia, body weight loss, muscle and fat depletion compared to TB 
controls. Similarly, TB animals with a knockdown of GLP-1 expression in the NTS 
had higher food intake, reduced body weight loss, and higher lean and fat mass 
compared to TB controls.  
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Our study identifies brainstem GLP-1 as crucial mediator of CACS in hepatoma TB 
rats. The GLP-1R represents a promising target against CACS and possibly other 
forms of disease-related anorexia/cachexia.  
 
Key	terms:	cancer,	food	intake,	energy	balance,	brainstem,	muscle	degradation.  
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1. INTRODUCTION 
 
The cancer anorexia-cachexia syndrome (CACS) causes a decline of the clinical 
status of cancer patients and often becomes a life-threatening condition (Laviano et 
al., 2003). CACS increases mortality, reduces treatment success and produces severe 
psychological suffering of patients and their families (Gordon et al., 2005; Kauth and 
Metz, 1987). We recently demonstrated the importance of the area postrema (AP) of 
the brainstem for the mediation of CACS in hepatoma tumour-bearing (TB) rats 
(Borner et al., 2016a). In order to identify a possible therapeutic target, our current 
study aimed to explore the role of the neuropeptide glucagon-like peptide-1 (GLP-1) 
in the brainstem as a mediator of CACS.  
GLP-1 is a posttranslational product of the peptide preproglucagon (PPG), which is 
expressed in enteroendocrine L-cells of the small intestine, in pancreatic α-cells 
(Eissele et al., 1992; Kauth and Metz, 1987) and in the nucleus tractus solitarii (NTS) 
(Merchenthaler et al., 1999), which is an integrative and relay center for enteroceptive 
signals controlling food intake (Grill and Hayes, 2009, 2012). GLP-1-expressing NTS 
neurons project to various GLP-1R expressing brain sites (Jin et al., 1988; Llewellyn-
Smith et al., 2011) implicated in the control of food intake and energy balance 
(Dunphy et al., 1998; Merchenthaler et al., 1999).  
Systemic and central administration of GLP-1 or the GLP-1R agonist exendin-4 
reduce food intake and body weight (Hayes, 2012; Hayes et al., 2010; Turton et al., 
1996) and brainstem GLP-1 signalling might also play a role in the physiological 
control of energy balance (Alhadeff et al., 2016; Barrera et al., 2011). Furthermore, 
GLP-1 signalling induces anorexia, nausea and food aversion in rodents and humans 
(Calara et al., 2005; Kanoski et al., 2012; Kinzig et al., 2002; Thiele et al., 1998). 
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The AP/NTS region is activated in TB rodents (Johnen et al., 2007; Ruud and 
Blomqvist, 2007), by the inflammatory endotoxin LPS, by the emetic agent LiCl, and 
by the chemotherapeutic drug cisplatin (Endo et al., 2004; Horn et al., 2007; 
Rinaman, 1999b). LPS and cisplatin-induced anorexia are attenuated in rats receiving 
fourth ventricular injection of the GLP-1R antagonist exendin-9 (Ex-9) (De Jonghe et 
al., 2016; Grill et al., 2004). Furthermore, central administration of Ex-9 attenuated 
LiCl-induced anorexia and blunts LiCl-induced AP activation (Rinaman, 1999a; 
Thiele et al., 1998). Therefore, we hypothesized that GLP-1 might also contribute to 
anorexia and cachectic body weight loss under chronic cancer conditions.   
 
We examined whether a pharmacological blockade of brainstem GLP-1R by chronic 
fourth ventricular infusion of Ex-9 blunts CACS. To confirm the involvement of local 
brainstem GLP-1 as a mediator of CACS, we knocked down PPG gene expression in 
the NTS by a lentiviral short-hairpin RNA (shRNA) approach.  
 
 
2. MATERIALS AND METHODS 
 
2.1 Animals and housing conditions 
 
Male Buffalo rats (Charles River Laboratory, USA) were housed at controlled 
temperature (21±1°C) under a 12-hour artificial light cycle with ad libitum access to 
standard laboratory rat chow (89025W16, Provimi Kliba, Switzerland). All 
experiments were approved by the Veterinary Office of the Canton Zurich 
(#95/2013). 
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2.2 Cell culture and tumour model 
 
The hepatoma tumour model and the Morris hepatoma 7777 cell culture procedures 
were described previously (Borner et al., 2016a). 
 
2.3	Fourth	ventricular	cannulation	
 
Rats (250-280 g) were placed in a stereotactic frame under isoflurane anaesthesia. A 
guide cannula (9mm 326OPG/Spc, Plastics One, USA) was implanted into the fourth	
ventricle. The coordinates for cannula placement (bregma -11.6 mm, lateral 0.0 mm, 
dorsoventral -7.2 mm) were chosen according to the rat brain atlas (Paxinos and 
Watson, 2006). After	recovery,	the	correct	placement	of	the	cannula	was	verified	by	measuring	 the	 hyperglycaemic	 response	 to	 fourth ventricular	 infusion	 of	 5-thio-D-glucose	(Ritter	et	al.,	1981).		
 
2.4 Lentiviral vectors 
High-titer (>109 IU/ml) lentiviral vectors dissolved in PBS, produced by Sigma-
Aldrich, were kindly provided by Dr. Shin Lee, ETHZ, Zurich, Switzerland. These 
viral vectors expressed a non-target sequence (control) shRNA or a shRNA directed 
against the rat PPG mRNA under the control of the human U6 promoter; the PPG 
shRNA oligonucleotide sequence was tgccaaacgtcatgatgaatt. In addition, the anti-
PPG vector contained an independent enhanced green fluorescent protein (turboGFP) 
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cassette that was used a reporter gene to confirm successful genomic integration and 
expression.  
 
2.5 Lentiviral shRNA knockdown of PPG gene expression in the NTS 
 
Rats (260-320 g) were anesthetized with an intraperitoneal injection of 50mg/kg 
ketamine and 6mg/kg xylazine and placed in a stereotactic frame with the head in a 
ventroflexed position. A midline incision was made above the occipito-atlantal joint, 
the muscles were retracted and the joint capsule was opened. A 10μl glass-syringe 
(Nanofil, World Precision Instrument, USA) equipped with a 35G bevelled needle 
(World Precision Instrument, USA) was attached to a stereotactic arm. Using a 
microinfusion pump (World Precision Instrument, USA), 2.0 μl of virus solution were 
infused bilaterally into the NTS over 20 min (400 μm	lateral	and	100	μm	caudal	to	the	obex,	and	600	μm	below	 the	surface	of	 the	brain).	These	coordinates	were	chosen	 to	 target	 the	 area	 of	 the	NTS	with	 the	 highest	 density	 of	 PPG	 neurons	(Barrera	et	al.,	2011;	Larsen	et	al.,	1997a).  
 
2.6 Tissue collection, qPCR, and confirmation of PPG knockdown  
After sacrifice, micro-punch samples (2 mm diameter) containing the AP/NTS region 
were obtained under a dissecting microscope on 3 consecutive 250 μm-thick coronal 
sections previously cut on a cryostat (Leica microsystem, Germany) and pooled 
together. Sections were collected starting 250 μm caudal to the obex. RNA was 
extracted and purified according to the manufacturer’s instructions (ReliaPrep, 
Promega, USA). cDNA was generated from the extracted RNA using the high 
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capacity cDNA reverse transcription kit (Applied Biosystems, USA). Quantitative 
polymerase chain reaction was performed using pre-designed Taqman probes 
(Thermoscientific, USA).  Rat S18 (Rn01428913) was used as housekeeping 
reference gene and the following probes were used to amplify PPG (Rn00562293), 
GLP-1R (Rn00562406), IL-1β (Rn00580432), TNF-α (Rn01525860), and IFN-γ 
(Rn00594078) transcripts. The relative expression was	 calculated	 using	 the	comparative	delta-delta	Ct	method.	Sample	were	run	in	duplicates.	
 
2.7 Measurement of energy expenditure 
 
The experiments involving Ex-9 treated rats were conducted in an open-circuit 
indirect calorimetric system (TSE Phenomaster, Germany). The animals were single-
housed in metabolic cages and adapted to the housing conditions for 7 days before the 
start of the experiment as previously described (Borner et al., 2016a). Food intake and 
body weight was measured daily before dark onset.   
 
 
2.8 Computed tomography (CT) scanning and muscle weight measurements 
 
Total carcass lean and fat volumes were measured by quantitative microcomputed 
tomography (La Theta LCT-100A scanner, Hitachi-Aloka Medical, Japan) as 
previously described (Borner et al., 2016b). After the CT scanning, the left 
gastrocnemius, tibialis and soleus muscles were dissected at the level of their upper to 
lower tendons and weighed. 
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2.9	Experiment	1:	Chronic	infusion	of	Ex-9	in	healthy	and	tumour-bearing	rats	
First,	we	 investigated	 the	effect	of	Ex-9	on	 food	 intake,	body	weight,	metabolic	rate	 and	 respiratory	 exchange	 ratio	 (RER)	 in	 non-tumour-bearing	 (NTB)	 rats.	Primed	 osmotic	 minipumps	 (model	 2ML2,	 ALZET,	 DURECT	 corporation,	 USA)	were	implanted	subcutaneously	into	the	left	flank	and	connected	to	the	cannula	via	a	subcutaneous	vinyl	catheter	(C312VT,	Plastics	One,	USA).	Minipumps	were	filled	with	Ex-9	(0,83	mg/ml)	or	saline	and	released	a	constant	amount	of	Ex-9	(100	 μg/day)	 directly	 into	 the	 fourth	 ventricle.	 In	 tumour-bearing	 rats,	minipumps	were	implanted	on	day	9	after	tumour	inoculation,	i.e.	at	the	typical	onset	of	the	anorectic	response	(Borner	et	al.,	2016a;	Borner	et	al.,	2016b).	The	infusion	 lasted	 for	 11	 days.	 Animals	 were	 euthanized	 with	 a	 lethal	intraperitoneal	dose	of	pentobarbital	 (100	mg/kg)	 injected	shortly	before	dark	onset	(see	above)	for	tissue	collection	and	carcass	analysis.	
	
2.10 Experiment 2: Effects of PPG gene expression knockdown in the NTS prior and 
during tumour growth 
Three	weeks	after	the	lentivirus	injection,	rats	were	single-housed	and	adapted	to	 the	 housing	 conditions	 for	 14	 days	 before	 tumour	 cell	 injection.	 PPG	knockdown	(PPG-KD)	and	control	animals	were	kept	in	BIODAQ	cages	(Research	Diets,	 USA).	 Daily	 food	 intake	 and	 body	 weight	 were	 measured	 daily	 shortly	
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before	 dark-onset.	 At	 the	 end	 of	 the	 experiment,	 animals	were	 euthanized	 for	tissue	collection	and	carcass	analysis	(see	above).	
	
2.11 Experiment 3: Measurements of brainstem PPG and GLP-1R expression, and 
circulating GLP-1 levels  
 
PPG and GLP-1R mRNA expression levels were analysed in non-operated TB, NTB, 
and NTB/pair-fed (PF) rats (220-250 g). Moreover, circulating GLP-1 levels were 
also measured. Rats were single-housed in BIODAQ cages. Daily food intake and 
body weight were measured shortly before dark-onset. Starting from nine days after 
tumour induction of the TB group, PF animals received the same amount of food that 
was consumed the previous day by the TB rats. Nineteen days after tumour-induction, 
animals were euthanized shortly before dark onset and brains were processed for gene 
expression analysis as described above. Blood was collected from the right ventricle 
of the heart in EDTA-coated tubes (Sarstedt, Germany) containing a DPP-IV inhibitor 
(1:100, Millipore, USA) and centrifuged at 7’000 x g (4°C, 7 min) to obtain plasma. 
The levels of GLP-1 were measured in triplicates using a commercial kit (Meso Scale 
Discovery, USA) according to the manufacturer instructions. 
 
 
2.12 Data evaluation and statistical analysis 
 
All data were expressed as mean ± SEM. In the Ex-9 studies, body weight changes 
were calculated by subtracting the weight of the animal at the day of minipump 
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implantation from the final body weight. In the experiments involving PPG-KD 
animals, body weight change was calculated by subtracting the body weight before 
the onset of the anorectic response (day 8 after tumour induction) from the body 
weight at the end of the experiment. Metabolic rate and RER were calculated as 
described previously (Borner et al., 2016b). For the experiment involving Ex-9 
treatment in healthy rats, the average values obtained from 2 consecutive days prior to 
minipump implantation were used as baseline and compared to the average values of 
treatment days 3 and 4. In the experiment involving TB animals treated with Ex-9, the 
values obtained between days 2-3 after tumour inoculation were used as baseline (i.e., 
prior to the onset of anorexia) and compared to the average values on days 12-13 after 
tumour induction (i.e. treatment days 3-4).  
 
Unpaired Student’s t-test was used for comparison between two groups. Statistical 
comparisons between multiple groups were performed using one-way ANOVA 
followed by Tukey’s post-hoc test. For all statistical tests, a p-value less than 0.05 was 
considered significant. Data were analysed using Prism GraphPad 5.0.  
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3. RESULTS 
 
 
3.1 Chronic fourth ventricular infusion of Ex-9 attenuated CACS in hepatoma 
tumour-bearing rats but did not affect energy balance in healthy rats 
 
Vehicle treated TB (Vehicle/TB) animals showed a clear anorectic response. In Ex-9 
treated TB (Ex-9/TB) rats, anorexia was markedly attenuated compared to controls 
(Figure 1A). On average, daily food intake was about 17% higher in Ex-9 treated rats 
compared to controls during the treatment period (Ex-9/TB: 16.3±0.4 g vs. 
Vehicle/TB: 13.9±0.6 g; p < 0.01; Figure 1B). Tumour-induced body weight loss was 
attenuated in rats receiving Ex-9 (Figure 1C). This appeared to be mainly due to a 
preservation of fat mass because Ex-9/TB rats had higher fat mass but similar total 
lean mass compared to Vehicle/TB animals (Figure 1D). However, Ex-9/TB rats had 
higher gastrocnemius and total hind limb muscle weights (i.e. sum of gastrocnemius, 
tibialis and soleus muscle mass) than TB controls (Fig. 1E). Relative to baseline 
conditions, control rats had significantly lower RER values on days 12-13 reflecting 
an increased lipid metabolism. While the tumour-dependent reduction in RER was not 
observed in the Ex-9/TB group, the RER of these animals did not significantly differ 
from the vehicle treated group (Fig. 1F). The metabolic rate was similar between Ex-
9/TB and Vehicle/TB animals before and during the treatment period (Fig. 1G). In 
addition, no differences in metabolic rate were detected when EE data were not 
corrected for body weight (data not shown).   Importantly, tumour weight did not 
differ significantly between Ex-9/TB and Vehicle/TB rats at the end of the experiment 
(17.5±1.1 vs. 14.2±1.2 g). 
	 13	
Under	 non-pathological	 conditions,	 chronic	 11-day	 infusion	 of	 Ex-9	 into	 the	fourth	ventricle	did	not	affect	daily	food	intake	(Fig.	1H-I),	body	weight	and	body	weight	gain	(Fig.	1J-K)	compared	to	control	animals.	Similarly,	no	change	in	body	composition	occurred	between	Ex-9	treated	rats	compared	to	controls,	and	Ex-9	treated	and	control	animals	did	not	differ	in	body	composition	(data	not	shown).	Moreover,	metabolic	rate	and	RER	were	similar	in	both	groups	and	no	significant	changes	occurred	during	treatment	(Fig.	1L-M).	
 
 
3.2 Knockdown of PPG expression in the NTS attenuated CACS 
 
Fig. 2A shows a representative histological photomicrograph of the right caudal NTS 
displaying GFP fluorescence 7 weeks after the lentiviral vector injection. The 
indicated target region (Fig. 2B) corresponds to the caudal NTS where PPG neurons 
are located (Larsen et al., 1997a). Seven weeks after the lentivirus injection, PPG-KD 
rats expressed significantly (-47%) less PPG mRNA in the AP/NTS region than 
controls (Fig. 2C). No change in GLP-1R expression occurred between the 
experimental groups (Fig. 2D). Furthermore, mRNA levels of TNF-α, IL-1β,	 and	
IFN-γ in the AP/NTS did not differ between PPG-KD and controls. The expression 
values of these markers were similar and not significantly different in non-operated 
NTB rats (TNF-α;	NTB: 1.00±0.13, Ctrl-KD: 0.95±0.41, PPG-KD: 0.85±0.24 (p>0.9 
for all comparisons), IL-1β;	 NTB: 1.00±0.12, Ctrl-KD: 1.73±0.94, PPG-KD: 
1.21±0.39 (p>0.7 for all comparisons)	 and	 IFN-γ;	 NTB: 1.00±0.08, Ctrl-KD: 
1.94±1.32, PPG-KD: 1.31±0.86 (p>0.7 for all comparisons).	 Hence, there was no 
indication of local inflammatory responses caused by the injection of lentivirus.  
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Both experimental groups showed similar food intake in the week prior to tumour cell 
inoculation (PPG-KD: 23.0±1.0 vs. controls 23.5±1.0 g/day) and prior to tumour 
anorexia (Fig 2E). Food intake of control animals decreased 10 days after tumour 
induction leading to a 30% reduction on the last day of the experiment compared to 
baseline (i.e. days 1-2 after tumour induction, Fig. 2E). On average, mean daily food 
intake was 26% higher in PPG-KD than controls from day 8 to the end of the 
experiment (Fig. 2G). Anorexia in control animals was associated with marked loss of 
body weight. This effect was significantly attenuated in PPG-KD animals beginning 
at day 13 (Fig. 2F-H). The body weight change between day 8 after tumour induction 
and the end of the experiment was -6.4±2.7 vs. -23.9±4.7 g (PPG-KD vs. controls; p < 
0.01). The differences in body weight were due to both higher lean and fat volumes 
(Fig. 2I). Despite the higher lean mass of the PPG-KD group, differences in hind limb 
muscle mass did not reach statistical significance (not shown). Tumour weight did not 
differ significantly between the two groups (PPG-KD: 11.9±1.1 vs. controls: 12.1±0.9 
g).  
 
3.3 Tumour growth decreased PPG expression without affecting circulating GLP-1 
and GLP-1R expression in the AP/NTS. 
 
Circulating active GLP-1 levels were not significantly different between NTB, PF and 
TB rats (Fig. 3A). Tumour-bearing animals had lower PPG expression compared to 
NTB rats. However, pair-feeding also reduced PPG expression to the level of the TB 
animals (Fig. 3B). No significant difference in AP/NTS GLP-1R expression levels 
occurred between the experimental groups (Fig. 3C).  
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4. DISCUSSION 
 
We identified GLP-1 as a neurochemical mediator of brainstem-dependent CACS 
providing first evidence that GLP-1 signalling in the caudal brainstem mediates 
cancer anorexia and subsequent body weight loss. A pharmacological and genetic 
blockade of GLP-1R signalling in the brainstem attenuated CACS.  
Under non-pathological conditions a blockade of brainstem GLP-1R does not affect 
energy intake or body weight development (Grill et al., 2004; Hayes et al., 2009; 
Zhao et al., 2012). Our findings are consistent with these studies because neither 
GLP-1R blockade nor PPG-KD affected food intake or body weight in NTB rats. 
Consequently, the anti-CACS effects described in our experiments are likely due to a 
specific blockade of a pathological activation of the GLP-1 system. 
Although peripherally administered GLP-1 reduces food intake and body weight 
(Punjabi et al., 2014; Ruttimann et al., 2009), our findings do not suggest a role of 
peripheral GLP-1 in the mediation of CACS. There was only a tendency of increased 
circulating GLP-1 in TB rats but the levels were not significantly different from NTB 
or pair-fed animals. Further, intestinal GLP-1 seems to act locally on GLP-1R on 
terminals of intestinal vagal afferents to reduce food intake (Krieger et al., 2016; 
Ruttimann et al., 2009), but vagal afferents are not required for CACS in this tumour 
model (Borner et al., 2016a). Our current study rather supports a role of brainstem-
derived GLP-1 and central GLP-1R in the mediation of CACS. The brainstem GLP-1 
system mediates acute behavioural sickness responses induced by LPS, LiCl and 
cisplatin (De Jonghe et al., 2016; Grill et al., 2004; Rinaman, 1999a). Food avoidance 
following malaise is a commonly known phenomenon, which not only occurs under 
these experimental conditions but also in cancer patients (Bernstein, 1985, 1999). 
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Anorexia and body weight loss induced by chronic treatment with the GLP-1R 
agonist exendin-4 is paralleled by nausea (pica behaviour) (Kanoski et al., 2012). 
Whether tumour-dependent food avoidance and aversive responses contribute to 
anorexia under our experimental conditions remains to be elucidated.   
Our studies do not identify the location of postsynaptic GLP-1R mediating CACS in 
our model. Fourth but not third ventricular injection of Ex-9 attenuates the anorectic 
effect of LPS indicating that blockade of hindbrain GLP-1R is sufficient to reverse 
acute sickness anorexia. Acute fourth ventricular infusions appear to be ineffective in 
the forebrain due to the rostral-to-caudal flow of the cerebrospinal fluid (Daniels and 
Marshall, 2012; Grill et al., 2004), but it cannot be excluded that Ex-9 might reach 
forebrain areas during chronic infusion into the fourth ventricle. A possible relevance 
of GLP-1-ergic signalling between the NTS and the AP is suggested by our recent 
finding that a specific lesion of the AP attenuates CACS (Borner et al., 2016a). 
However, the presence of axon terminals from PPG neurons to the AP has so far only 
been confirmed in mice (Llewellyn-Smith et al., 2011). Since AP neurons may also 
function as first order upstream neurons that activate downstream PPG neurons in the 
NTS, it is currently unknown how the AP interacts with the NTS in the mediation of 
GLP-1 dependent CACS.  
Other possible downstream targets for PPG neurons reside in the lateral parabrachial 
nucleus (LPBN), the dorsal raphe nuclei, and in the hypothalamus (e.g. 
paraventricular nucleus, PVN). GLP-1ergic projections to calcitonin gene-related 
peptide (CGRP) expressing neurons in the LPBN suppress food intake. Interestingly, 
CGRP neurons mediate cancer anorexia in mice (Campos et al., 2017).  
There are also projections from PPG neurons of the NTS to serotonergic neurons 
located in brainstem raphe nuclei (Llewellyn-Smith et al., 2011). The serotoninergic 
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system is implicated in CACS (Laviano et al., 2005; van Norren et al., 2017) and 
LPS-induced anorexia (von Meyenburg et al., 2003). Recently, GLP-1R-dependent 
reduction in food intake and body weight has been linked to activation of serotonin 
(5-HT) neurons in the dorsal raphe nucleus (Anderberg et al., 2017). Whether 5-HT is 
a downstream mediator of GLP-1 in the context of CACS is unknown. Axonal 
terminals from GLP-1 neurons of the NTS form synaptic contacts with Corticotropin-
releasing hormone (CRH) neurons in the PVN (Ghosal et al., 2013). Central infusion 
of GLP-1 activates CRH neurons in the PVN and leads to increased 
adrenocorticotropin (ACTH) and corticosterone plasma levels (Kinzig et al., 2003; 
Larsen et al., 1997b). Therefore, a GLP-1 dependent activation of the PVN might not 
only contribute to anorexia, but also to a glucocorticoid-induced loss of body weight, 
as it has been demonstrated under conditions of acute and chronic stress (Ghosal et 
al., 2017). 
 
 
It might appear surprising that the positive effect of Ex-9 treatment on hind limb 
muscle mass was not paralleled by increased whole body lean mass. Vice versa, PPG-
KD rats had higher total lean mass but no increased hind limb muscle mass. It should 
be mentioned, however, that PPG-KD animals were sacrificed 4 days earlier than 
those in the Ex-9 experiment. Hence, muscle atrophy may not have been advanced at 
that stage, which could account for the lack of a statistically significant treatment 
effect on muscle mass.  
While GLP-1 blockade improved energy intake in TB rats, the metabolic rate was not 
affected. The cachectic effect in hepatoma TB rats is partly independent of reduced 
energy intake because TB rats lose more body weight and muscle mass than pair-fed 
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NTB animals (Borner et al., 2016a). Therefore, a relative increase in energy 
expenditure appears to contribute to CACS in this tumour model. While we did not 
explore the effects of peripheral Ex-9 administration on CACS, additional beneficial 
effects might occur in the periphery also with respect to energy balance. At least in 
diet-induced obese mice, peripheral treatment with a GLP-1R agonist increased basal 
energy expenditure presumably via increased expression of uncoupling proteins in 
different tissues including muscle (Tomas et al., 2015). Moreover, stimulation of 
GLP-1R increased oxygen consumption and thermogenic gene expression in muscle 
cells, which can be blocked by Ex-9 (Choung et al., 2017).  
GLP-1R expression levels in the AP/NTS were unaffected by tumour growth or pair-
feeding. Tumour growth decreased PPG expression levels in the NTS. However, no 
difference was found between PF and TB animals, indicating that the decrease in PPG 
expression during tumour growth is likely due to a change in eating or body weight 
rather than specific tumour-dependent effects. Despite the lower NTS GLP-1 
expression levels following tumour growth, GLP-1 blockade was effective in 
attenuating CACS. Changes in PPG mRNA expression may not necessarily correlate 
with GLP-1 abundance or synaptic release. Further studies are required to investigate 
this aspect. 
 
 
Although we identified GLP-1 as neuronal mediator of CACS, it remains unknown 
how NTS PPG neurons are activated under tumour conditions. Recent studies suggest 
a role of the macrophage inhibitory cytokine-1 (MIC-1) in CACS, which acts via the 
AP/NTS region to reduce food intake and body weight (Johnen et al., 2007; Tsai et 
al., 2014). Our model is characterized by increased levels of MIC-1 in the absence of 
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other inflammatory circulating cytokines (Borner et al., 2016a; Ruud and Blomqvist, 
2007). MIC-1 primarily activates non-catecholaminergic neurons in the NTS (Tsai et 
al., 2014). GLP-1-expressing neurons are not catecholaminergic (Larsen et al., 
1997a), but it is currently unknown whether MIC-1 activates GLP-1 expressing NTS 
neurons. Interestingly, a specific receptor for MIC-1 (GFRAL, GDNF family receptor 
alpha like) was recently identified (Emmerson et al., 2017; Mullican et al., 2017; 
Yang et al., 2017). In the brain, GFRAL is exclusively expressed in the AP/NTS 
region. Not only the AP but also the NTS is accessible by blood-borne mediators 
(Broadwell and Sofroniew, 1993). Hence, NTS PPG neurons could be directly or 
indirectly activated by MIC-1 and possibly other circulating cytokines leading to 
GLP-1 release in downstream projection sites (Fig. 4).  
 
In summary, we found GLP-1/GLP-1R signalling in the brainstem to be required for 
the central mediation of CACS in hepatoma TB rats. A blockade of brainstem GLP-1 
not only attenuated anorexia, but also body weight loss and muscle wasting. Future 
studies should address the question whether brainstem GLP-1 might mediate anorexia 
and cachexia in other cancer or chronic disease models.  Moreover, it remains to be 
established which stimuli activate the brainstem GLP-1 system under these sickness 
conditions. Based on our findings, GLP-1R antagonists may be therapeutically useful 
for the treatment of CACS and possibly other form of sickness-anorexia. 
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Figure legends:  
 
Fig. 1 Chronic central Ex-9 treatment attenuated CACS but did not affect 
energy balance in non-tumour-bearing rats 
A-B) Ex-9 (100 μg/day) administered chronically into the fourth ventricle  
significantly attenuated the anorectic response induced by tumour growth. C) Ex-9 
treated rats showed attenuated tumour-dependent body weight loss following 
treatment. Ex-9 treated animals had higher fat mass than controls (D) and higher 
gastrocnemius, and total muscle mass (sum of gastrocnemius, tibialis and soleus 
muscle mass) compared to tumour-bearing controls (E). F) Following tumour 
induction, control rats had significantly lower RER values relative to baseline 
conditions, reflecting a shift towards lipid oxidation. Ex-9 treatment did not prevent 
this tumour-induced effect. G) Metabolic rate did not significantly differ between 
groups. In non-tumour-bearing rats, Ex-9 infusion did not affect food intake (H-I), 
body weight or body weight gain (J-K). Ex-9 treatment did not alter respiratory 
exchange ratio and metabolic rate (L-M). Baseline data were collected for two 
consecutive days prior to minipump implantation. Data analysed using the Student’s 
t-test, * p < 0.05, ** p < 0.01 (A-E and H-K) or with one-way ANOVA followed by 
Tukey’s post-hoc test (F-G and L-M). Different letters indicate significant differences 
(p<0.05). 
  
 
Fig. 2 Lentiviral PPG-specific shRNA injection into the NTS significantly 
decreased PPG mRNA expression and attenuated anorexia, and loss of body 
weight by preservation of lean and fat mass 
A) Representative image of GFP fluorescence in the NTS seven weeks after lentivirus 
infusion, indicating successful transfection. Scale bar 50 μm. B) Location of NTS 
target area for lentiviral PPG knockdown. Bregma level -14.64. Gr, gracile nucleus; 
SolC, commissural nucleus of the solitary tract; Sol, nucleus of the solitary tract; 10, 
dorsal motor nucleus of the vagus; CC, central canal. Modified image from The Rat 
Brain in Stereotaxic Coordinates, Paxinos, G. and Watson, C., Copyright Paxinos, G. 
and Watson, C. (1998), with permission from Elsevier. C-D) Quantification of PPG 
and GLP-1R mRNA levels in the AP/NTS of rats injected with lentivirus encoding for 
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a PPG-specific shRNA or control lentivirus. E-F) PPG knockdown in the NTS 
strongly attenuated anorexia and body weight loss induced by tumour growth without 
affecting baseline food intake before tumour induction. G-H) From day 8 onwards, 
PPG KD animals showed significantly increased food intake and lost significantly 
less body weight compared to controls. I) The higher body weight of PPG KD 
animals was due to by higher lean and fat volumes compared to tumour-bearing 
controls. Data analysed using the Student’s t-test, * p < 0.05, ** p < 0.01, *** p < 
0.001. 
 
 
Fig. 3 Tumour growth did not affect circulating GLP-1, and PPG and GLP-1R 
expressions levels in the AP/NTS 
A) Circulating GLP-1 did not significantly differ between groups. B) Tumour-bearing 
rats (TB) and pair-fed animals (PF) had lower PPG expression levels in the AP/NTS 
compared to non-tumour-bearing controls (NTB). C) GLP-1R expression was similar 
among all groups. Data analysed with one-way ANOVA followed by Tukey’s post-
hoc test. Means with different letter are significantly different from each other 
(p<0.05). 
 
 
 
Fig. 4 Possible mechanisms contributing to GLP-1-depedent	mediation	of	CACS.	Humoral	mediators	 such	as	 the	macrophage	 inhibitory	 cytokine	1	 (MIC-1)	 and	other	 cytokines	 may	 directly	 or	 indirectly	 (e.g.	 via	 the	 area	 postrema	 (AP))	activate	GLP-1	expressing	neurons	located	in	the	nucleus tractus solitarii (NTS). In 
the brain, the MIC-1 receptor GFRAL is exclusively expressed in the AP/NTS region. 
Local release of GLP-1 in downstream projection sites might lead to activation of 
neuropeptide/neurotransmitter systems known to be involved in pathological anorexia 
and body weight loss (see text for further explanations).  
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